1Division of Nephrology, University Health Network, Toronto, Ontario, Canada

2Division of Cardiology, Women's College Hospital, Toronto, Ontario, Canada

3British Columbia Provincial Renal Agency, Vancouver, British Columbia, Canada

4Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

5St. Paul's Hospital, Vancouver, British Columbia, Canada

Correspondence: Dr. Ayodele Odutayo, Division of Nephrology, Toronto General Hospital, University Health Network, 200 Elizabeth Street, Toronto, Ontario, M5G 2C4, Canada. Email: [email protected]

See related article, “Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study,” on pages 592–601.